|
|
Article: Bristol-Myers Squibb and Otsuka Pharmaceutical Co., Ltd. Submit New Drug Application for Aripiprazole.
- Article from:
- PR Newswire
- Article date:
- November 7, 2001
CopyrightCOPYRIGHT 2001 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
New Antipsychotic Drug May Provide Help for the
Two Million Americans with Schizophrenia
PRINCETON, N.J., and TOKYO, Nov. 7 /PRNewswire/ --
Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Company, Ltd. today announced that a New Drug Application (NDA) has been submitted to the U.S. Food and Drug Administration (FDA) for aripiprazole, an investigational novel drug for the treatment of schizophrenia. If approved, aripiprazole will become the first member of the next generation of atypical antipsychotics.
The filing is based on an extensive global clinical development program for aripiprazole, involving numerous ...